Phase IIb/III Trials

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

Merck plans July shipments of the single-dose antibody ahead of the 2025 RSV season with a CDC advisory review scheduled for late June.